Vontobel Asset Management Inc. lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 4.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,579,734 shares of the medical equipment provider’s stock after selling 67,281 shares during the quarter. Vontobel Asset Management Inc.’s holdings in Boston Scientific were worth $51,665,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BSX. FMR LLC boosted its holdings in shares of Boston Scientific by 10.4% in the 2nd quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock valued at $5,121,554,000 after buying an additional 14,711,069 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Boston Scientific by 8.7% in the 1st quarter. BlackRock Inc. now owns 106,292,471 shares of the medical equipment provider’s stock valued at $2,903,912,000 after buying an additional 8,510,783 shares during the last quarter. Epoch Investment Partners Inc. acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $116,062,000. TD Asset Management Inc. boosted its holdings in shares of Boston Scientific by 531.8% in the 2nd quarter. TD Asset Management Inc. now owns 2,488,256 shares of the medical equipment provider’s stock valued at $81,366,000 after buying an additional 2,094,436 shares during the last quarter. Finally, Eaton Vance Management boosted its holdings in shares of Boston Scientific by 42.3% in the 1st quarter. Eaton Vance Management now owns 6,564,617 shares of the medical equipment provider’s stock valued at $179,345,000 after buying an additional 1,951,777 shares during the last quarter. 90.94% of the stock is owned by hedge funds and other institutional investors.

BSX traded down $0.05 during trading hours on Friday, reaching $35.94. The company’s stock had a trading volume of 92,913 shares, compared to its average volume of 5,942,683. Boston Scientific Co. has a 52 week low of $24.54 and a 52 week high of $37.30. The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62. The stock has a market cap of $49.44 billion, a PE ratio of 28.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.63.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07. The firm had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS. equities analysts forecast that Boston Scientific Co. will post 1.39 earnings per share for the current year.

Several equities research analysts have recently commented on BSX shares. Morgan Stanley increased their price objective on Boston Scientific from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Piper Jaffray Companies increased their price objective on Boston Scientific to $38.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Jefferies Financial Group reissued a “hold” rating and issued a $34.00 price objective on shares of Boston Scientific in a report on Thursday, July 26th. Stifel Nicolaus reissued a “buy” rating and issued a $37.00 price objective on shares of Boston Scientific in a report on Thursday, July 26th. Finally, Needham & Company LLC reissued a “strong-buy” rating on shares of Boston Scientific in a report on Friday, July 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $35.86.

In other Boston Scientific news, SVP Jeffrey B. Mirviss sold 19,323 shares of the stock in a transaction on Thursday, June 14th. The stock was sold at an average price of $32.64, for a total transaction of $630,702.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP David A. Pierce sold 5,000 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $32.42, for a total value of $162,100.00. Following the transaction, the executive vice president now owns 29,201 shares in the company, valued at approximately $946,696.42. The disclosure for this sale can be found here. Insiders have sold a total of 136,393 shares of company stock worth $4,619,864 in the last quarter. Company insiders own 0.73% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Hedge Funds

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.